Evidence map›Paper›PMID 38473215›Full record

ArticleCancers2024

Statin-Sensitive Akt1/Src/Caveolin-1 Signaling Enhances Oxidative Stress Resistance in Rhabdomyosarcoma.

Silvia Codenotti, Leonardo Sandrini, Delia Mandracchia, Luisa Lorenzi, Giovanni Corsetti, Maura Poli, Michela Asperti, Valentina Salvi, Daniela Bosisio, Eugenio Monti and 9 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. The Mevalonate Pathway in the Radiation Response of Cancer.International journal of radiation oncology, biology, physics · 2025
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Silvia CodenottiDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Leonardo SandriniDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-9878-8016
Delia MandracchiaDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-7101-013X
Luisa LorenziDepartment of Molecular and Translational Medicine, University of Brescia, and ASST Spedali Civili di Brescia, 25123 Brescia, Italy.ORCID 0000-0003-2483-2955
Giovanni CorsettiDepartment of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-0326-0644
Maura PoliDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-9206-8122
Michela AspertiDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Valentina SalviDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Daniela BosisioDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-6276-5365
Eugenio MontiDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-4742-7445
Stefania MitolaDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-5557-738X
Luca TriggianiDepartment of Radiation Oncology, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy.
Michele GuesciniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy.ORCID 0000-0001-9372-7038
Enrico PozzoDepartment of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-3362-3509
Maurilio SampaolesiDepartment of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-2422-3757
Stefano GastaldelloDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0000-0001-7369-8452
Matteo CassandriDepartment of Radiological Sciences, Oncology and Anatomic Pathology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2919-676X
Francesco MaramponDepartment of Radiological Sciences, Oncology and Anatomic Pathology, "Sapienza" University of Rome, 00161 Rome, Italy.
Alessandro FanzaniDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-7475-2668
University of Brescia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITKU Leuven · BESapienza University of Rome · ITKarolinska Institutet · SEUniversity of Urbino · IT

Funding

Fondazione Umberto Veronesi 5064Italian Association for Cancer Research ID. 24696Italian Association for Cancer Research ID. 25726
6 · The paper itself

Abstract

Identifying the molecular mechanisms underlying radioresistance is a priority for the treatment of RMS, a myogenic tumor accounting for approximately 50% of all pediatric soft tissue sarcomas. We found that irradiation (IR) transiently increased phosphorylation of Akt1, Src, and Cav1 in human RD and RH30 lines. Synthetic inhibition of Akt1 and Src phosphorylation increased ROS levels in all RMS lines, promoting cellular radiosensitization. Accordingly, the elevated activation of the Akt1/Src/Cav1 pathway, as detected in two RD lines characterized by overexpression of a myristoylated Akt1 form (myrAkt1) or Cav1 (RDCav1), was correlated with reduced levels of ROS, higher expression of catalase, and increased radioresistance. We found that treatment with cholesterol-lowering drugs such as lovastatin and simvastatin promoted cell apoptosis in all RMS lines by reducing Akt1 and Cav1 levels and increasing intracellular ROS levels. Combining statins with IR significantly increased DNA damage and cell apoptosis as assessed by γ histone 2AX (γH2AX) staining and FACS analysis. Furthermore, in combination with the chemotherapeutic agent actinomycin D, statins were effective in reducing cell survival through increased apoptosis. Taken together, our findings suggest that the molecularly linked signature formed by Akt1, Src, Cav1, and catalase may represent a prognostic determinant for identifying subgroups of RMS patients with higher probability of recurrence after radiotherapy. Furthermore, statin-induced oxidative stress could represent a treatment option to improve the success of radiotherapy.

Indexed as

Akt1catalasecaveolin-1radioresistancerhabdomyosarcomaSrc

Identifiers

PMID38473215
PMCPMC11154391
OpenAlexW4391985139

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.